2023 Q1 – NSCLC Essentials Readout
By Chris Mamrosh

Adoption of Newly-Approved 1L mNSCLC Regimens Driven by Promotional Activities

Promotion plays a major role in the successful launch of a new pharmaceutical product. Companies must develop a marketing strategy that effectively communicates the benefits of the therapy and differentiates it from competitors. The promotional strategy then is executed through a combination of channels including sales representative detailing, digital awareness, and other non-personal engagement tactics.

InCrowd’s newest Essentials research highlights the importance of promotion surrounding the launch of a new product with insights focused on the Non-Small Cell Lung Cancer (NSCLC) market.

In Nov 2022, two treatment regimens received FDA approval for use in 1L metastatic Non-Small Cell Lung Cancer (mNSCLC):

  • Regeneron’s LIBTAYO + chemo (Nov 8)
  • AstraZeneca’s IMFINZI + IMJUDO + chemo (Nov 11)

InCrowd’s Essentials syndicated market tracker monitored the awareness, perceptions, and adoption of these regimens throughout the first quarter of 2023.

The research revealed the following key findings:

  • Adoption of the newly-approved regimens was modest in Q1 2023. LIBTAYO + chemo captured 2% of 1L mNSCLC PD-L1 prescribing. IMFINZI + IMJUDO + chemo captured 3% of the market. Less than one-quarter of oncologists reported prescribing either regimen.
  • Promotional campaigns were very focused on a subset of prescribers. Both Regeneron and AstraZeneca executed focused promotional campaigns in Q1 2023, reaching less than half of relevant oncologists across a combination of channels, rep delivered and digital.
  • Promotional activities played a major role in oncologist adoption of the newly-approved regimens. Eighty-five percent of LIBTAYO + chemo patient share and 95% of IMFINZI + IMJUDO + chemo patient share, came from the less than 50% of oncologists who received promotions from the respective manufacturers. This skew is not observed for established players in the market.
  • Healthcare professionals (HCPs) receiving a combination of rep and digital promotions reported higher prescribing than those receiving only rep, only digital, or none. Seventy percent of LIBTAYO + chemo patient share came from the 18% of oncologists who received both rep and digital promotions in the past month. Eighty-two percent of IMFINZI + IMJUDO + chemo patient share came from the 27% of oncologists who received both rep and digital promotions in the past month.

To learn more about Essentials, contact us.

Related Resources

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.